HUSH Restriction in HIV Infected Patients
- Conditions
- HIV Infections
- Interventions
- Other: Blood sampling
- Registration Number
- NCT04172480
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Brief Summary
HIV eradication faces a major obstacle that is viral persistence in latent reservoir cells despite antiretroviral therapy. Epigenetic repression plays a central role in viral transgene latency and several epigenetic regulators have been involved in this process. Among them, the "Human Silencing Hub" or HUSH complex, composed of Tasor, MPP8 and periphilin, has been shown to recruit the H3K9me3 methyltransferase "SET domain bifurcated 1" (SETDB1) and is therefore responsible for genes' epigenetic repression. Our recent results highlight the ability of Vpx from HIV-2/SIVsmm to counteract HUSH and to reactivate latent viruses in a latency model. We propose here to study HUSH activity along pathogenesis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description acute HIV1 infection Blood sampling Patient infected by HIV1, prior treatment initiation chronic HIV1 infection Blood sampling Patient infected by HIV1, untreated or without treatment since at least 3 months HIV2 infection Blood sampling Patient infected by HIV2, untreated or without treatment since at least 3 months
- Primary Outcome Measures
Name Time Method Hush activity Baseline Transcription rate of cellular genes targeted by HUSH by qRT-PCR
Viremia Baseline Intracellular HIV RNA load expressed in number of copies / ml
Total HIV DNA and integrated HIV DNA Baseline Quantification by qPCR
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Hôpital Bicêtre
🇫🇷Le Kremlin-Bicêtre, France
Hôtel-Dieu
🇫🇷Paris, France
Hôpital Necker
🇫🇷Paris, France